OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action

Dec 27, 2018

OPKO Health Reports Third Quarter 2018 Financial Results

Nov 9, 2018

BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services

Nov 8, 2018

OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018

Nov 8, 2018

OPKO Confirms Resumption of Common Stock Trading on Nasdaq

Sep 14, 2018

OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock

Sep 11, 2018

OPKO Comments on SEC Complaint

Sep 7, 2018

OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients

Sep 4, 2018

OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical Trial

Aug 28, 2018

OPKO Health Reports Second Quarter 2018 Financial Results

Aug 7, 2018